Compounds and methods for treating candidiasis and aspergillus infections

Patent metadata

Field	Value
Publication number	US-2016287586-A1
Application number	US-201414535640-A
Country	US
Kind code	A1
Filing date	Nov 7, 2014
Priority date	Jan 18, 2012
Publication date	Oct 6, 2016
Grant date	—

Abstract

The present disclosure provides compounds, or pharmaceutically acceptable salts thereof, for killing or inhibiting the growth of a Candida or Aspergillus species or preventing or treating a mammal having candidiasis (oral and/or disseminated) or an Aspergillus infection.

First claim

1 - 76 . (canceled)

77 . A method of preventing or treating a human having oral or disseminated candidiasis or an aspergillus infection comprising administering to the human in need thereof an effective amount of a compound of Formula IV:

wherein:
R 1 and R 2 are, independently, —C(═NH)NH 2 , —(CH 2 ) n NH 2 , or —(CH 2 ) n NC(═NH)NH 2 , where n is 2, 3, or 4;

or a pharmaceutically acceptable salt thereof.

78 - 252 . (canceled)

253 . The method of claim 77 wherein R 1 and R 2 are, independently, —C(═NH)NH 2 , —(CH 2 ) n NH 2 , or —(CH 2 ) n NC(═NH)NH 2 , where n is 2 or 3.

254 . The method of claim 77 wherein R 1 and R 2 are, independently, —C(═NH)NH 2 or —(CH 2 ) n NH 2 , where n is 2 or 3.

255 . The method of claim 77 wherein the compound is:

or a pharmaceutically acceptable salt thereof.

256 . The method of claim 77 wherein the compound, or pharmaceutically acceptable salt thereof, that is administered to the human is in a pharmaceutical composition comprising a pharmaceutically acceptable carrier.

257 . The method of claim 256 wherein the pharmaceutical composition is in a unit dosage form.

258 . The method of claim 257 wherein the unit dosage form is a packaged preparation.

259 . The method of claim 257 wherein the unit dosage form is a tablet or capsule.

260 . The method of claim 77 wherein the human has oral or disseminated candidiasis infection.

261 . The method of claim 77 wherein the human has an aspergillus infection.

Assignees

• Cellceutix Corp
• Univ Rutgers

Inventors

• Scott Richard W
• Freeman Kathryn B
• Tang Haizhong
• Diamond Gill

Classifications

• A61P31/10

  Antimycotics · CPC title

• A61K31/506 Primary

  not condensed and containing further heterocyclic rings · CPC title

• A61P17/00

  Drugs for dermatological disorders · CPC title

• C07D239/28

  with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms · CPC title

• C07D409/14

  containing three or more hetero rings · CPC title